早期术后表皮生长因子受体抑制：体内抑制口腔鳞状细胞癌微小残留的安全性和有效性。
Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.
机构信息
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
出版信息
Head Neck. 2013 Mar;35(3):321-8. doi: 10.1002/hed.22961. Epub 2012 Feb 24.
Abstract
BACKGROUND
The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process.
METHODS
The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process.
RESULTS
EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing.
CONCLUSION
These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.
摘要
背景
手术后晚期口腔鳞状细胞癌（OSCC）的局部区域复发是由于残留肿瘤细胞的再生，这些细胞可能在伤口愈合过程中受到表皮生长因子受体（EGFR）配体的刺激。
方法
检测了 OSCC 切除和游离皮瓣供区人引流液（DF）中 EGFR 配体的水平。建立了微小残留 OSCC 的小鼠模型，并使用西妥昔单抗进行治疗，以测量肿瘤生长、存活和颈部淋巴结转移。还建立了一个伤口愈合模型，以评估 EGFR 抗体对伤口愈合过程的影响。
结果
在 OSCC 切除部位发现了 EGFR 配体。EGFR 靶向治疗可延缓微小残留 OSCC 疾病模型中的肿瘤再生，而对局部伤口愈合无明显影响。
结论
这些结果为临床评估该方法治疗局部区域晚期 OSCC 患者提供了强有力的依据。
相似文献
1
Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.早期术后表皮生长因子受体抑制：体内抑制口腔鳞状细胞癌微小残留的安全性和有效性。
Head Neck. 2013 Mar;35(3):321-8. doi: 10.1002/hed.22961. Epub 2012 Feb 24.
2
Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.西妥昔单抗联合金雀异黄素治疗对口腔鳞状细胞癌具有相加的抗癌作用。
Cancer Lett. 2010 Jun 1;292(1):54-63. doi: 10.1016/j.canlet.2009.11.004. Epub 2009 Dec 2.
3
Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.抗 EGFR 抗体西妥昔单抗由口腔鳞状细胞癌分泌，并改变 EGF 驱动的上皮-间充质转化。
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1267-1272. doi: 10.1016/j.bbrc.2018.07.035. Epub 2018 Jul 13.
4
A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.口腔鳞状细胞癌中桥粒芯糖蛋白 3 与表皮生长因子受体的潜在联系及其对西妥昔单抗治疗效果的影响。
Exp Dermatol. 2019 May;28(5):614-617. doi: 10.1111/exd.13920.
5
Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.尼妥珠单抗增强光动力疗法在口腔肿瘤模型中的抗肿瘤作用。
Oncotarget. 2015 May 30;6(15):13487-505. doi: 10.18632/oncotarget.3622.
6
Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study.EGFR 和 PD-L1 的多光谱荧光成像用于口腔鳞状细胞癌的精准检测：一项临床前和临床研究。
BMC Med. 2024 Aug 26;22(1):342. doi: 10.1186/s12916-024-03559-w.
7
8
The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue.抗内皮生长因子受体和抗血管内皮生长因子受体2联合靶向治疗对淋巴结转移的影响：一项在舌鳞状细胞癌原位裸鼠模型中的研究
Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):411-20. doi: 10.1001/archoto.2009.14.
9
Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.口腔鳞状细胞癌细胞对西妥昔单抗的耐药性与表皮生长因子受体不敏感及增强的干细胞样潜能有关。
Oncol Rep. 2014 Aug;32(2):780-6. doi: 10.3892/or.2014.3258. Epub 2014 Jun 12.
10
EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.EGFR 介导的信号通路影响口腔鳞状细胞癌对 JQ1 的敏感性。
J Cell Biochem. 2018 Oct;119(10):8368-8377. doi: 10.1002/jcb.26920. Epub 2018 Jul 3.
引用本文的文献
1
Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook.纳米技术在头颈癌围手术期治疗中的应用与展望
Front Bioeng Biotechnol. 2025 Mar 27;13:1566522. doi: 10.3389/fbioe.2025.1566522. eCollection 2025.
2
Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes.评估肿瘤淋巴结清扫术后远处转移灶的微转移灶。
BMC Cancer. 2018 May 30;18(1):608. doi: 10.1186/s12885-018-4538-8.
3
Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration.磷酸甘油酸变位酶1预示口腔鳞状细胞癌的不良预后并与细胞迁移相关。
J Cancer. 2017 Jul 5;8(11):1943-1951. doi: 10.7150/jca.19278. eCollection 2017.
4
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.厄洛替尼联合放射治疗晚期皮肤鳞状细胞癌的Ⅰ期研究。
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1275-81. doi: 10.1016/j.ijrobp.2012.09.030. Epub 2012 Nov 22.
本文引用的文献
1
Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients.头颈部癌患者接受联合放疗和西妥昔单抗治疗后的伤口愈合情况。
J Wound Care. 2011 Apr;20(4):166-70. doi: 10.12968/jowc.2011.20.4.166.
2
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.诱导化疗联合西妥昔单抗治疗局部晚期头颈部鳞状细胞癌：一项 II 期前瞻性试验的结果。
J Clin Oncol. 2010 Jan 1;28(1):8-14. doi: 10.1200/JCO.2009.23.0425. Epub 2009 Nov 16.
3
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.术后早期使用紫杉醇，随后对切除的高危头颈部鳞状细胞癌患者同步给予紫杉醇和顺铂并进行放射治疗：II期试验RTOG 0024报告
J Clin Oncol. 2009 Oct 1;27(28):4727-32. doi: 10.1200/JCO.2008.21.4197. Epub 2009 Aug 31.
4
The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue.抗内皮生长因子受体和抗血管内皮生长因子受体2联合靶向治疗对淋巴结转移的影响：一项在舌鳞状细胞癌原位裸鼠模型中的研究
Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):411-20. doi: 10.1001/archoto.2009.14.
5
Growth factors and cytokines in wound healing.伤口愈合中的生长因子和细胞因子。
Wound Repair Regen. 2008 Sep-Oct;16(5):585-601. doi: 10.1111/j.1524-475X.2008.00410.x.
6
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
7
The interaction of radiation therapy and antiangiogenic therapy.放射治疗与抗血管生成治疗的相互作用。
Cancer J. 2008 Jul-Aug;14(4):207-13. doi: 10.1097/PPO.0b013e3181836af3.
8
Metastasis of squamous cell carcinoma of the oral tongue.舌鳞状细胞癌的转移
Cancer Metastasis Rev. 2007 Dec;26(3-4):645-62. doi: 10.1007/s10555-007-9082-y.
9
Characterization of wound drainage fluids as a source of soluble factors associated with wound healing: comparison with platelet-rich plasma and potential use in cell culture.伤口引流液作为与伤口愈合相关的可溶性因子来源的特性：与富血小板血浆的比较及在细胞培养中的潜在用途。
Wound Repair Regen. 2007 Jul-Aug;15(4):511-20. doi: 10.1111/j.1524-475X.2007.00259.x.
10
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.针对头颈部鳞状细胞癌中的表皮生长因子受体信号传导
Br J Cancer. 2007 Feb 12;96(3):408-16. doi: 10.1038/sj.bjc.6603566. Epub 2007 Jan 16.
Zotero 插件